Edward Sathoff, MD
Psychiatry · Mankato, MNNPI 1093794950
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$232
- Corium, LLC$145
- Teva Pharmaceuticals USA, Inc.$136
- Harmony Biosciences LLC$101
- Alkermes, Inc.$98
- Acadia Pharmaceuticals Inc$96
- plus $631 from 19 others
What the payments were for
- Food & beverage$1,441100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 12 | $232 |
| Corium, LLC | 14 | $145 |
| Teva Pharmaceuticals USA, Inc. | 5 | $136 |
| Harmony Biosciences LLC | 4 | $101 |
| Alkermes, Inc. | 7 | $98 |
| Acadia Pharmaceuticals Inc | 6 | $96 |
| Neuronetics, Inc. | 3 | $89 |
| Ironshore Pharmaceuticals Inc. | 6 | $83 |
| Almatica Pharma LLC | 4 | $54 |
| Tris Pharma Inc | 3 | $46 |
| AbbVie(2 entities) | 3 | $42 |
| Indivior Inc. | 2 | $39 |
| Vanda Pharmaceuticals Inc. | 2 | $35 |
| Soleno Therapeutics, Inc. | 2 | $30 |
| Eisai Inc. | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 3 | $27 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $26 |
| Lundbeck LLC | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Sage Therapeutics, LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
How this compares
$1,441 in reported general payments places this provider in the 90th percentile of 552 psychiatry providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 45 | $669,278 |
| AuvelityDextromethorphan Hbr/Bupropion | 321 | $328,161 |
| VraylarCariprazine Hcl | 144 | $245,831 |
| TrintellixVortioxetine Hydrobromide | 359 | $242,834 |
| IngrezzaValbenazine Tosylate | 32 | $217,554 |
| RexultiBrexpiprazole | 116 | $202,918 |
| Austedo XrDeutetrabenazine | 12 | $170,277 |
| LybalviOlanzapine/Samidorphan Malate | 49 | $152,156 |
| VyvanseLisdexamfetamine Dimesylate | 141 | $60,007 |
| NuplazidPimavanserin Tartrate | 12 | $59,380 |
| SpravatoEsketamine Hcl | 24 | $53,672 |
| ClozarilClozapine | 57 | $50,936 |
| CaplytaLumateperone Tosylate | 30 | $47,862 |
| Lurasidone Hcl | 208 | $42,476 |
| Invega SustennaPaliperidone Palmitate | 12 | $40,728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $136 | $839,55557 claims |
| Axsome Therapeutics, Inc.Auvelity | $17 | $328,161321 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse, Adderall | $16 | $311,931513 claims |
| AbbVieVraylar, Fetzima, Namzaric, Savella | $42 | $288,090199 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $14 | $217,55432 claims |
| Alkermes, Inc.Lybalvi | $98 | $152,15649 claims |
| Johnson & JohnsonSpravato, Invega Sustenna, Concerta | $13 | $130,54490 claims |
| Acadia Pharmaceuticals IncNuplazid | $96 | $59,38012 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $26 | $47,86230 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $27 | $27,71314 claims |
| Eisai Inc.Dayvigo | $30 | $14,78940 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 552 psychiatry providers in Minnesota.
Other psychiatry in Mankato
- Michael FarnsworthMankato$548K
- Danielle Magness-WellmannMankato$232K
- Robert OlsonMankato$1K
- Veronica RadiganMankato$496
- Michael MoellerMankato$483
- Sujit VarmaEdina$581K
- Craig VineSt Paul$136K
- Thomas WinegardenChanhassen$55K
- John LuehrMinnetonka$41K
- Walter RushSaint Paul$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.